A phase 1, single center, 1 sequence, 3 period, open label, multiple doses study to evaluate the drug-drug interaction of JMKX000623 tablet and metformin.
The drug-drug interaction study is meant to evaluate the pharmacokinetics and safety of JMKX000623 tablet combined metformin in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
24
JMKX000623, administered orally ;
Metformin,administered orally
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Area Under the Dosing Time Curve During the Dosing Interval After Reaching Steady State(AUC0-tau)
Time frame: baseline through 4 days post-dose
Maximum observed After Reaching steady state concentration (Css,max)
Time frame: baseline through 4 days post-dose
Adverse events (AEs)
Incidence and features of AEs assessed by CTCAE v5.0.
Time frame: baseline through 4 days post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.